PATH | VRL
Menu

Baseline Meningococcal Carriage in Burkina Faso Before the Introduction of a Meningococcal Serogroup A Conjugate Vaccine

The vaccine MenAfriVac has the potential to confer herd immunity by reducing carriage prevalence of epidemic strains. To better understand this phenomenon, the authors of this article, published in Clinical and Vaccine Immunology, initiated a meningococcal carriage study to determine the baseline carriage rate and serogroup distribution before vaccine introduction in the 1- to 29-year old population in Burkina Faso, the group chosen for the first introduction of the vaccine. A multiple cross-sectional carriage study was conducted in one urban and two rural districts in Burkina Faso in 2009. Carriage prevalence was the highest in the rural districts and in the dry season, but serogroup distribution also varied by district. This study forms a solid basis for evaluating the impact of MenAfriVac introduction on serogroup A carriage. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Kristiansen PA, Diomandé F, Wei SC, et al.

Published: 2011

» Visit web page (English)

(Located at cvi.asm.org)

Citation: Kristiansen PA, Diomandé F, Wei SC, et al. Baseline Meningococcal Carriage in Burkina Faso Before the Introduction of a Meningococcal Serogroup A Conjugate Vaccine. Clinical and Vaccine Immunology. 2011;18(3):435–443.

Resource types: Peer-reviewed journal

Diseases/vaccines: Meningococcus

Topics: Disease burden and surveillance

Regions: Africa